ALNA Allena Pharmaceuticals Inc.

4.61
0  0%
Previous Close 4.61
Open
Price To Book 2.48
Market Cap 95,962,055
Shares 20,816,064
Volume 0
Short Ratio
Av. Daily Volume 90,797

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data from first Phase 3 trial due 2H 2019.
Reloxaliase ALLN-177 (URIROX-1)
Enteric Hyperoxaluria
Phase 2 detailed data due June 21-22, 2019 at OHF and top-line data due 2H 2019.
Reloxaliase ALLN-177 (Study 206)
Primary hyperoxaluria
Phase 3 trial initiated 4Q 2018.
Reloxaliase ALLN-177 (URIROX-2)
Enteric Hyperoxaluria

Latest News

  1. The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
  2. Allena Pharmaceuticals Announces Interim Results from Study 206 of Reloxaliase in High Risk Patients with Advanced Oxalate Disorders
  3. Allena Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
  4. All You Need to Know About Allena Pharmaceuticals, Inc. (ALNA) Rating Upgrade to Buy
  5. Allena Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update
  6. Investors Who Bought Allena Pharmaceuticals (NASDAQ:ALNA) Shares A Year Ago Are Now Down 52%
  7. Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors
  8. Allena Pharmaceuticals Announces Agreement with Duke Clinical Research Institute for URIROX-2 Pivotal Phase 3 Trial
  9. Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  10. Allena Pharmaceuticals, Inc. to Present at 39th Annual Cowen & Co. Health Care Conference
  11. Allena Pharmaceuticals Announces Appointment of Louis Brenner, M.D. as Chief Executive Officer and Confirms Key Milestones for 2019
  12. Allena Pharmaceuticals Achieves Alignment with FDA on Phase 3 Program and Accelerated Approval Pathway for Reloxaliase in Enteric Hyperoxaluria
  13. Do Hedge Funds Love Allena Pharmaceuticals, Inc. (ALNA)?
  14. Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences — Renewed Outlook, Key Drivers of Growth
  15. Allena Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
  16. Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November